Lymphatic ERG signaling and fibrosis in scleroderma
Official title: Lymphatic ERG signaling in scleroderma fibrosis
Funded at Boston University Medical Campus · NIH-11336853 · Data updated 2026-11-12
This grant explores how a key gene pathway involved in lymphatic vessels may contribute to fibrosis in scleroderma, with the goal of finding new targets to improve vascular health and tissue healing.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Boston University Medical Campus NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | July 7, 2022 |
| Project end | May 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $525,939 |
| NIH project number | 5R01AR080950-05 |
| Project ID | NIH-11336853 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with scleroderma (systemic sclerosis) or related vascular/fibrotic manifestations may benefit from future therapies informed by this research.
✕Less likely to help
People without scleroderma or without vascular or fibrotic complications related to the condition may not be directly affected.
What this research studies
In scleroderma, blood vessel and lymphatic problems contribute to scarring and organ damage. The researchers will study how the ERG transcription factor affects the growth and function of both blood and lymphatic vessels, especially when injury and scarring occur. They plan to use models that mimic human disease to uncover how ERG influences wound healing and fibrosis. The findings could point to new points for therapy to improve vascular repair and reduce fibrosis in patients. This work aims to translate basic biology into potential treatments for scleroderma-related vascular disease.
Why it matters
Potential benefit: If successful, the work could identify new molecular targets to improve blood and lymphatic vessel repair and reduce fibrosis in scleroderma patients.
How similar studies have gone: Previous work shows lymphatic/vessel signaling pathways can influence fibrosis, suggesting this approach could yield meaningful insights, though it remains exploratory.
Where this research is happening
-
Boston University Medical Campus
Boston, United States Active
Researchers
- Principal investigator: Trojanowska, Maria — Boston University Medical Campus
- Study coordinator: Trojanowska, Maria
Related research
Other NIH-funded projects on the same topics.
-
New mouse and human lung models to study how T cells drive scleroderma-related lung fibrosis
Aims to understand how specific T cell types contribute to lung scarring in scleroderma by using advanced mouse and human lung models.
-
Investigating lymphatic signaling in scleroderma fibrosis
This study is looking at how certain signals in the lymphatic system might affect people with scleroderma, with the goal of finding new ways to improve treatments for this condition.
-
New treatment for lung fibrosis related to scleroderma
This study is looking at a new treatment made from collagen that could help people with lung fibrosis caused by scleroderma, aiming to improve their health and quality of life more effectively than current options.
-
Investigating the role of a specific protein in lung fibrosis related to scleroderma
This study is looking at how a protein called BHLHB2 affects lung scarring in people with scleroderma, hoping to find new ways to help treat lung problems caused by this condition.
-
Interface between immune cells and scarring in the eye
This grant looks at how immune cells influence scar formation in the cornea after injury and how this affects vision.
-
How often to treat schistosomiasis to protect the liver
A randomized trial will test different frequencies ofPraziquantel treatment to prevent liver damage in people aged 15–40 with schistosomiasis in Uganda.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.